Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization.
Hsin-Lun LeeJo-Ting TsaiChun-You ChenYing-Chun LinChin-Beng HoLai-Lei TingChia-Chun KuoI-Chun LaiChun-Yu LinJui-Hsiang TangYu-Min HuangWei-Yu KaoSheng-Wei ChengChia-Ning ShenShang-Wen ChenJeng-Fong ChiouPublished in: Therapeutic advances in medical oncology (2019)
SABR can serve as a salvage treatment for patients with HCC with BCLC stage C disease unsuitable for TACE, in particular, in those with a baseline CLIP score of ⩽1. A BED10 of ⩾85 Gy is an appropriate prescribed dose for tumor control. Because out-field relapse is the major cause of treatment failure, SABR in combination with novel systemic modalities should be investigated in future studies.